Ideas
Upstream space benefits from cheaper launches.
The upstream space economy, including launch vehicles, satellites, ground equipment, and related research, is becoming more attractive because SpaceX has drastically reduced launch and orbit-insertion costs, enabling the whole space market to grow. He expects upstream to take a larger share of the space economy over time, with launch, satellite, and ground-station demand reinforcing each other.
Korea can become top-three space power.
Korea's rocket technology and manufacturing internalization are strong enough that it is already among major space powers. With Nuri technology transferred to Hanwha Aerospace and private-sector involvement expanding, Korea can soon reach the top three in space and rocket capability, supporting the domestic space industry.
Hyundai Motor has robot manufacturing edge.
Hyundai Motor can receive robot-related valuation because it already has the factories and equipment needed to manufacture robots. Its manufacturing infrastructure is a competitive advantage as robotics scales.
Hanwha Aerospace is preferred Korean space play.
Hanwha Aerospace is his preferred Korean space company. Its defense cash flow from K9 and Chunmoo exports remains strong, and the space narrative from Nuri technology transfer and private space leadership can justify its high valuation. He views pullbacks as opportunities, and target prices have been raised by more than 20% while he still sees it as attractive.
Rocket Lab is second in private launch.
Rocket Lab is the clear second-place private launch provider after SpaceX. It has rapidly followed SpaceX, increased rocket size, and is one of only two private companies with a real launch business, giving it a strong position as launch demand grows.
KOSPI dip before 5,000 is opportunity.
The KOSPI pullback before the symbolic 5,000 level is a risk-off and position-squaring move, not the end of the rally. He expects the index to break 5,000 and for that level to become support, so the current correction should be viewed as a buying opportunity; deleveraging could make the market healthier.
Memory leads and is still cheap.
Memory remains the real market leader, not space. The future growth and earnings path is already visible and is being exceeded daily, and Samsung Electronics and SK hynix are the top two. He says memory is not a bubble and is still cheap; on market drops, investors should buy memory.
Oil is key inflation risk to watch.
He is watching oil more than rates. Oil is rising and remains a key inflation input; if oil cannot be contained, inflation will stay sticky and pressure interest-rate expectations. That would be a risk for long-duration space and biotech stocks.
Korean biotech near-term unattractive.
Korean biotech is facing a combined negative from Alteogen's disappointing contract disclosure, rate sensitivity, and supply rotation into humanoid and other growth themes. Although it may eventually refill and rebound, buying the first drop is not recommended; near-term narrative is weak and approaching now is burdensome.
Obesity royalty economics may worsen.
Global big pharma price competition in obesity treatments is compressing drug prices. Companies that licensed out obesity assets may see future royalty streams and valuations cut because analysts value them off sales-linked royalties. The more obesity drugs become mainstream, the worse the licensing and royalty economics may become.
This 3PRO TV (삼프로TV) video, published January 21, 2026,
features Kwon Taek-jung
discussing Space upstream sector, Korean space industry, 005380.KS, 012450.KS, RKLB, EWY, SMH, 005930.KS, 000660.KS, WTI, Korean biotech sector, Obesity treatment license-out companies.
10 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Kwon Taek-jung
· Tickers:
Space upstream sector,
Korean space industry,
005380.KS,
012450.KS,
RKLB,
EWY,
SMH,
005930.KS,
000660.KS,
WTI,
Korean biotech sector,
Obesity treatment license-out companies